佳緣科技(301117.SZ):網絡安全業務已有多型安全平台和安全專用芯片通過國防領域客户的高度認可和在軌驗證
格隆匯11月10日丨佳緣科技(301117.SZ)近期在接待機構投資者調研時表示,公司網絡安全業務已經有多型安全平台和安全專用芯片通過了國防領域客户的高度認可和在軌驗證,裝備工藝能力優異、質量可靠、工作穩定,有力保障了國家網絡安全需求。公司不斷加大投入編碼技術與人工智能預先研究,深耕衞星組網安全防護和數據鏈防護領域發展,推動公司在航天、航空等領域安全產品數字化製造的升級,助力公司在航天、航空、數據中心和終端安全等領域的全面佈局,強化公司在市場的核心競爭力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.